[New England Journal of Medicine] Investigators enrolled patients from a compassionate-use program and those from a Phase I study who had primary multirefractory autoimmune hemolytic anemia. Each patient received a single infusion of autologous CD19 CAR T cells.

[Nature Medicine] Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel, 27 developed CAR T cell therapy-associated immune-related adverse events (CirAEs). This included one remarkable case with three distinct CirAEs in association with an extreme CD4⁺ CAR T cell expansion.

[Nature Medicine] Scientists conducted a case study of a child with spinal muscular atrophy type 1 experiencing substantial hepatitis after receiving onasemnogene abeparvovec, undertaking long- and short-read metagenomic sequencing of liver tissue.

[Nature Biotechnology] The authors demonstrated that an engineered UGA-sup-tRNA gene, designed with transcriptional regulatory elements, can be efficiently packaged into recombinant AAV for in vivo delivery.

[Nature Immunology] Investigators showed that BACH2 dose-dependently regulates long-term stem-like differentiation and antitumor immunity of CAR T cells.

[Nature Immunology] Researchers showed that 41BB induces BACH2, a transcriptional regulator that directs stem and memory programs.

[Molecular Therapy] The authors used single-cell RNA sequencing to analyze bone marrow aspirate concentrate and stromal vascular fraction samples in a clinical trial of autologous cell therapies.

[Journal of Immunotherapy of Cancer] Five distinct CARs were designed based on available monoclonal antibody sequences that target mutant calreticulin and were subsequently used to generate CAR-T cells.

[Blood Advances] Researchers investigated the effect of antiplatelet agents on the efficacy of platelet-FVIII in HA mice. 2bF8Tg mice express FVIII in platelets controlled by the αIIb promoter and were treated with aspirin, clopidogrel, or the αIIbβ3-blocking antibody Leo.H4.

[Trends in Molecular Medicine] The authors provide a comprehensive summary of published studies that have used scRNA-seq to analyze clinical CAR-T cells, focusing on T cell exhaustion, cytotoxicity, memory, expansion, clonal diversity, and cytokines.

[Journal of Immunotherapy of Cancer] Scientists provide the current landscape and growing potential of cell therapies in sarcomas, including TCR-T, CAR-T cells, tumor-infiltrating lymphocytes, natural killer cells, and mesenchymal stromal cells.

[University of Colorado Anschutz] A research team from Gates Institute at University of Colorado Anschutz has been awarded $1 million from Blood Cancer United^® to advance a new immunotherapy approach for patients with treatment-resistant acute myeloid leukemia.